Orthocell Limited
OCC.AX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$156.63M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $156.63 Million |
|---|---|
| Enterprise Value | $151.04 Million |
| Earnings per Share | $-0.05 |
| Beta | -0.06 |
| Outstanding Shares | 272,253,637 |
Return
| Return on Equity | -65.34% |
|---|---|
| Return on Assets | -41.02% |
| Return on Invested Capital | -66.08% |
Valuation & Multiples
| P/E Ratio | -10.85 |
|---|---|
| PEG | -55.12 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.48 |
| Enterprise Value to EBIT | -4.92 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$3.80 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 19, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$6.75 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Orthocell Limited
37 employees
CEO: Paul Frederick Anderson
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations...